In the United States, more than 70,000 people are diagnosed with non-Hodgkin’s lymphoma each year, which is caused by excessive proliferation of immune cells in the body’s lymph nodes. The most common is diffuse large B-cell lymphoma (DLBCL), which accounts for about 1/3 of lymphomas, and about half of these tumors are resistant to chemotherapy and immunotherapy. Sakali limfoma asalna tina jaringan limfatik, sumebarna sél nyababkeun struktur sakabéh jaringan beueus, sareng sél kakeunaan gaya mékanis sapertos aliran cairan.
Panaliti ngajajah kumaha kakuatan cairan ieu aya hubunganana sareng résistansi tumor, sareng ngembangkeun alat "limfoma microreactor" anu ngalaan limfoma manusa kana aliran cairan, sami sareng pola dina pembuluh limfa sareng sababaraha titik limfa.
Mikroreactor aliran-sisi tim kalebet ruang kabudayaan sél anu nyambung kana ruang sedeng budaya (cairan) ngalangkungan saluran résistansi anu sempit, anu ngalambatkeun aliran cairan pikeun mensimulasikeun pembuluh limfa sareng bagian simpul limfa. Nalika uji coba subpopulasi anu béda tina limfoma DLCBL, tim panilitian mendakan yén sababaraha subtipe diklasifikasikeun numutkeun mutasi dina molekul reséptor sél B anu aya dina permukaan sél diréspon béda-béda kana kakuatan cairan. Tim mendakan yén kakuatan cairan ngatur tingkat éksprési integrin-adhesin sareng reséptor sél B. Aya gangguan antar antara integrin sareng sinyal reséptor sél B, anu tiasa ngabantosan résistansi sababaraha tumor.
What is remarkable is that the same tumor subtype responds differently to mechanical forces. If we can understand the role of biophysical stimulation, we can know why some lymphomas are sensitive to treatment, while others are refractory, then we will be able to treat more patients. It is important to understand the factors that regulate B-cell receptor signaling because this pathway is a key target for new therapeutic drugs, and several of them are in clinical trials. Kanggo langkung jelasna, punten nelepon KankerFax.
